Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Stelljes M, Bornhauser M, Kroger M, Beyer J, Sauerland MC, Heinecke A, Berning B, Scheffold C, Silling G, Buchner T, Neubauer A, Fauser AA, Ehninger G, Berdel WE, Kienast J; Cooperative German Transplant Study Group. Stelljes M, et al. Among authors: heinecke a. Blood. 2005 Nov 1;106(9):3314-21. doi: 10.1182/blood-2005-04-1377. Epub 2005 Jul 14. Blood. 2005. PMID: 16020510 Free article. Clinical Trial.
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, Sauerland MC, Berdel W, Buchner T, Hiddemann W. Kern W, et al. Among authors: heinecke a. Blood. 2003 Jan 1;101(1):64-70. doi: 10.1182/blood-2002-02-0532. Epub 2002 Jun 28. Blood. 2003. PMID: 12393605 Free article. Clinical Trial.
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
Büchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, Schnittger S, Kern W, Tchinda J, Reichle A, Lengfelder E, Staib P, Ludwig WD, Aul C, Eimermacher H, Balleisen L, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W. Büchner T, et al. Among authors: heinecke a. J Clin Oncol. 2006 Jun 1;24(16):2480-9. doi: 10.1200/JCO.2005.04.5013. J Clin Oncol. 2006. PMID: 16735702 Clinical Trial.
Maintenance for acute myeloid leukemia revisited.
Büchner T, Krug U, Berdel WE, Heinecke A, Sauerland MC, Wörmann B, Hiddemann W. Büchner T, et al. Among authors: heinecke a. Curr Treat Options Oncol. 2007 Aug;8(4):296-304. doi: 10.1007/s11864-007-0041-1. Curr Treat Options Oncol. 2007. PMID: 18058075 Review.
Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial.
Stelljes M, Beelen DW, Braess J, Sauerland MC, Heinecke A, Berning B, Kolb HJ, Holler E, Schwerdtfeger R, Arnold R, Spiekermann K, Müller-Tidow C, Serve HL, Silling G, Hiddemann W, Berdel WE, Büchner T, Kienast J; German AML Cooperative Group (AMLCG). Stelljes M, et al. Among authors: heinecke a. Haematologica. 2011 Jul;96(7):972-9. doi: 10.3324/haematol.2011.041004. Epub 2011 Apr 1. Haematologica. 2011. PMID: 21459795 Free PMC article. Clinical Trial.
Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis.
Stelljes M, Krug U, Beelen DW, Braess J, Sauerland MC, Heinecke A, Ligges S, Sauer T, Tschanter P, Thoennissen GB, Berning B, Kolb HJ, Reichle A, Holler E, Schwerdtfeger R, Arnold R, Scheid C, Müller-Tidow C, Woermann BJ, Hiddemann W, Berdel WE, Büchner T. Stelljes M, et al. Among authors: heinecke a. J Clin Oncol. 2014 Feb 1;32(4):288-96. doi: 10.1200/JCO.2013.50.5768. Epub 2013 Dec 23. J Clin Oncol. 2014. PMID: 24366930 Clinical Trial.
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W, Haferlach T, Fonatsch C, Haase D, Schoch C, Hossfeld D, Lengfelder E, Aul C, Heyll A, Maschmeyer G, Ludwig WD, Sauerland MC, Heinecke A. Büchner T, et al. Among authors: heinecke a. Blood. 1999 Jun 15;93(12):4116-24. Blood. 1999. PMID: 10361108 Free article. Clinical Trial.
Transplantation strategies in AML: AMLCG data.
Kienast J, Stelljes M, Berning B, Kröger M, Sauerland MC, Heinecke A, Schoch C, Wörmann B, Büchner T, Hiddemann W, Berdel WE; German AML Cooperative Group. Kienast J, et al. Among authors: heinecke a. Ann Hematol. 2004;83 Suppl 1:S136-7. doi: 10.1007/s00277-004-0850-2. Ann Hematol. 2004. PMID: 15124707 Clinical Trial.
Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma.
Kropff MH, Lang N, Bisping G, Dominé N, Innig G, Hentrich M, Mitterer M, Südhoff T, Fenk R, Straka C, Heinecke A, Koch OM, Ostermann H, Berdel WE, Kienast J. Kropff MH, et al. Among authors: heinecke a. Br J Haematol. 2003 Aug;122(4):607-16. doi: 10.1046/j.1365-2141.2003.04473.x. Br J Haematol. 2003. PMID: 12899716 Free article. Clinical Trial.
244 results